The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Value Expansion Is Expected For The Claudin 18.2 Targeted Therapy Market Over The Forecast Period?
The claudin 18.2 targeted therapy market has recently experienced substantial growth. It is projected to expand from $1.6 billion in 2025 to $1.98 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 23.7%. This historic expansion can be linked to several factors, including the rising incidence of gastric and gastrointestinal cancers, innovations in antibody engineering technologies, the proliferation of oncology-focused clinical trials, increasing financial contributions to targeted cancer therapies, and a more refined comprehension of claudin protein biology.
The market for claudin 18.2 targeted therapy is projected to experience rapid expansion over the coming years. This market is anticipated to reach a valuation of $4.61 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 23.5%. This projected increase can be attributed to several factors such as more regulatory clearances for targeted cancer medications, a heightened need for individualized cancer care, broader application of combination treatment methods, increased investments in oncology drug development, and the growing uptake of accurate diagnostic tools. Key developments during this timeframe are expected to involve a greater emphasis on biomarker-guided cancer therapies, the accelerated creation of claudin 18.2 monoclonal antibodies, the expanding availability of targeted treatments for specific conditions, improved incorporation of companion diagnostic tools, and a rise in strategic alliances within precision oncology.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28169&type=smp
Which Strategic Drivers Are Supporting The Claudin 18.2 Targeted Therapy Market Development?
The growing incidence of gastrointestinal cancers is anticipated to fuel the expansion of the claudin 18.2 targeted therapy market in the future. Gastrointestinal (GI) cancers are defined as malignant tumors developing anywhere in the digestive tract, from the esophagus to the rectum. This increase in GI cancers is largely linked to unhealthy diets, particularly those rich in processed foods and low in fiber, which contribute to gut inflammation and heightened cancer risk. Claudin 18.2 targeted therapy treats these cancers by specifically targeting the Claudin 18.2 protein, which is overexpressed on cancer cells. This selective action allows drugs or antibodies to destroy cancer cells while leaving healthy tissue unharmed, thereby improving treatment effectiveness. For example, in June 2025, the Centers for Disease Control and Prevention (CDC), a US public health agency, stated that 147,931 new colorectal cancer cases were reported in 2022, and 53,779 deaths from colorectal cancer were recorded in 2023. Hence, the increasing prevalence of gastrointestinal cancers is a significant driver for the growth of the Claudin 18.2 targeted therapy market.
Which Segment-Based Categories Are Covered In The Claudin 18.2 Targeted Therapy Market?
The claudin 18.2 targeted therapy market covered in this report is segmented –
1) By Therapy Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Therapy Types
2) By Indication: Gastric Cancer, Pancreatic Cancer, Esophageal Cancer, Other Indications
3) By Route Of Administration: Intravenous, Oral, Other Route Of Administrations
4) By End-User: Hospitals, Oncology Centers, Research Institutes, Other End-Users
Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Bispecific Antibodies: Igg-Like Bispecific Antibodies, Non-Igg-Like Bispecific Antibodies
3) By Antibody-Drug Conjugates: Microtubule Inhibitor-Based Antibody-Drug Conjugates, Dna Damaging Agent-Based Antibody-Drug Conjugates, Topoisomerase Inhibitor-Based Antibody-Drug Conjugates
4) By Other Therapy Types: Car-T Cell Therapy, Vaccines, Small Molecule Inhibitors
Which Trends Are Supporting The Evolution Of The Claudin 18.2 Targeted Therapy Market?
Leading companies in the claudin 18.2 targeted therapy market are concentrating on developing innovative solutions, such as monoclonal antibodies, to specifically target cancer cells expressing claudin 18.2 and enhance treatment outcomes. A monoclonal antibody is a laboratory-engineered protein designed to precisely bind to a single target, like a protein on the surface of cancer cells, thereby assisting the immune system in recognizing and attacking these cells. For instance, in March 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, received approval from Japan’s Ministry of Health, Labour and Welfare for VYLOY (zolbetuximab) for the treatment of patients with CLDN18.2-positive cancer. This targeted therapy for advanced gastric and gastroesophageal junction cancer selectively binds to the CLDN18.2 protein on tumor cells, activating the immune system to destroy cancer cells. Clinical trials indicated it significantly improves progression-free and overall survival when combined with chemotherapy compared to chemotherapy alone. This innovative therapy presents a new, effective option for patients with HER2-negative, CLDN18.2-positive tumors, addressing an unmet need in aggressive gastric cancer.
Which Companies Are Engaged In The Claudin 18.2 Targeted Therapy Market Environment?
Major companies operating in the claudin 18.2 targeted therapy market are Bristol Myers Squibb Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Shanghai Henlius Biotech Inc., Legend Biotech Corporation, Zai Lab Limited, Harbour Biomed Ltd., CARsgen Therapeutics Holdings Limited, Genor Biopharma Co. Ltd., Phanes Therapeutics Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Triumvira Immunologics Inc., SOTIO Biotech a.s., Leap Therapeutics, Allogene Therapeutics, AskGene Pharma Inc., Elpiscience Biopharmaceutical Co. Ltd., I-Mab Biopharma Co. Ltd., Antegene Biopharma Co. Ltd.
Access The Complete Claudin 18.2 Targeted Therapy Market Report:
https://www.thebusinessresearchcompany.com/report/claudin-182-targeted-therapy-global-market-report
Which Region Stands As The Largest Contributor To The Claudin 18.2 Targeted Therapy Market?
Asia-Pacific was the largest region in the claudin 18.2 targeted therapy market in 2025. The regions covered in the claudin 18.2 targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Claudin 18.2 Targeted Therapy Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=28169&type=smp
Browse Through More Reports Similar to the Global Claudin 18.2 Targeted Therapy Market 2026, By The Business Research Company
Targeted Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report
Coronavirus Current Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/coronavirus-current-therapy-global-market-report
Next Generation Antibody Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model